The technological advances in the field of hematology have enabled researchers to advance the use of embryonic stem cells in the production of red blood cells.
FREMONT, CA: Hematology has witnessed significant progress over the last decade. The development of robust hematology analyzers with the integration of various technological solutions has enabled researches to seamlessly recognize the type of blood and generate complete blood count (CBC). Advances have also been made in the field of cellular therapy.
Hemotherapy is widely leveraged for establishing hemostasis during the treatment of specific conditions. The procedure involves the transfusion of whole blood or its fractions, including red blood cells, platelets, or plasma, into the patients. However, blood transfusions are often hindered by severe conditions such as acute lung injuries and hemolytic transfusion reaction (HTR).
A successful blood transfusion requires immunological compatibility between the donor and recipient, not only to avoid adversities such as HTR but also to promote therapeutic efficiency. As a result, it is imperative for the providers to identify the antigens in the blood cells and determine the immune status of the recipient before the procedure. It has spurred researchers to work toward the development of universal red blood cells, which can be transfused in the patient regardless of the difference in their blood components.
Researchers are leveraging the robust technological solution to facilitate the production of red blood cells. The utilization of stem cells can pave the way for the development of blood cells, addressing the needs of the health systems. However, there are many challenges that need to be overcome.
The production of red blood cells requires a highly scalable and cost-effective manufacturing process. The current technologies cannot support the production of red blood cells needed for even a small amount of blood. To meet this need, researchers are testing various biological engineering approaches.
The development of embryonic stem cells (ESCs) can potentially facilitate an inexhaustible source of blood cells. The cells can also differentiate into the various tissues, including hematopoietic differentiation. Although large scale production of blood cells is still in development, significant progress has been made in the field of ESCs. Further research into ESCs can potentially pave the way for the development of new cell types which can fulfill the need of healthcare.